EXPRESSION OF INTEGRIN ALPHA7 IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS | ||||
| ALEXMED ePosters | ||||
| Article 1, Volume 5, Issue 4, December 2023, Page 19-20 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2023.244606.1716 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hanaa Abdel Meguid Elaggan1; Ahmed Bedewy1; Sarah Medhat Nawar1; Ahmed Abdelrahman Shehata2; Aya Mohamed Hassanein  1
| ||||
| 1Department of Hematology, Medical Research Institute, Alexandria University | ||||
| 2Department of Hematology, Faculty of Medicine, Alexandria University | ||||
| Abstract | ||||
| Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell malignancy in which immature hematopoietic cells proliferate and accumulate in the bone marrow, peripheral blood and other tissues. Some patients may have the emergence of abnormal myeloid clones in the bone marrow, termed clonal hematopoiesis, years before diagnosis. It accounts for 25% of all types of leukemia being the most common leukemia in adults, and is ranked as the sixth highest cause of death because of cancer in males worldwide. AML has greater predominance in the elderly compared to the overall population. Integrin alpha7 (ITGA7), a member of the extracellular matrix binding proteins and one of the integrin family of adhesion molecules, is located on chromosome 12p13 and consists of over 27 exons spanning a region of about 22.5 kb. It participates in various cellular processes and has been recognized as a tumour promoter in a number of solid carcinomas. | ||||
| Keywords | ||||
| Acute myeloid leukemia (AML); INTEGRIN ALPHA7; response to induction chemotherapy | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 25 |
||||
